Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemon-C Study: Lenalidomide/Rituximab Maintenance in PCNSL
NCT04627753Phase 2Recruiting
- Start
- Nov 2020
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and rituximab in primary central nervous system lymphoma (PCNSL). Primary endpoint: 1-year Progression-Free Survival. Started Nov 2020; status: recruiting.
02
Drugs
lenalidomiderituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04627753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627753.